Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial
Asia-Pacific Psychiatry · 2021-06 · 13 (2)
DOI: 10.1111/appy.12445 ↗At a glance
Randomisierte kontrollierte Studie in Asia-Pacific Psychiatry, published online on 2020-11-04. Written by Narges Sharifzadeh and 9 co-authors. Institution: Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Major MEDLINE topics: Autism Spectrum Disorder, Autistic Disorder. Cited 33 times so far (Crossref); 29 references. Funded by: Mashhad University of Medical Sciences.
Topics: Kinderkrankenpflege
Abstract (original language)
Introduction
This study aimed to determine the safety and efficacy of treatment with autologous bone marrow mesenchymal stem cell (BMMSCs) compared with the routine treatment in children with autism spectrum disorder (ASD).
Methods
In this ethically approved randomized controlled trial, 32 ASD children aged 5‐15 years were randomly assigned to receive either autologous BMMSC plus rehabilitation therapy and risperidone (intervention group) or rehabilitation therapy and risperidone (control group). Autologous BMMSCs were intrathecally injected in the intervention group twice in 4 weeks. Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale‐second edition (GARS‐II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention.
Results
Overall, 32 patients in two groups of intervention (n = 14) and control (n = 18) completed the study, of which 27 (84.4%) were male. Mean age was 9.50 ± 2.14 years. The improvements in CARS total score, GARS‐II autism index, and CGI global improvement showed no significant differences between the groups over 12 months. However, the main effect for time*group interaction was significant regarding the CGI‐severity of illness, showing a significantly more pronounced improvement in the intervention group (F = 6.719; P = .002).
Discussion
Intrathecal injection of autologous BMMSCs seems to be safe and feasible, but has limited clinical efficacy in treatment of children with ASD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Pediatric Hematology and Oncology, Dr Sheikh Pediatric Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
- Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- General Directorate of Welfare, State Welfare Organization of Razavi Khorasan, Mashhad, Iran.
- Department of Community Medicine, School of Medicine, Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.
ORCID profiles: Mahsa Nahidi
Funding
- Mashhad University of Medical Sciences
Cite
APA
Sharifzadeh, N., Ghasemi, A., Tavakol Afshari, J., Moharari, F., Soltanifar, A., Talaei, A., Pouryousof, H. R., Nahidi, M., Fayyazi Bordbar, M. R., & Ziaee, M. (2021). Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. Asia-Pacific Psychiatry, 13(2). https://doi.org/10.1111/appy.12445
Vancouver
Sharifzadeh N, Ghasemi A, Tavakol Afshari J, Moharari F, Soltanifar A, Talaei A, et al. Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. Asia-Pacific Psychiatry. 2021;13(2). doi:10.1111/appy.12445
BibTeX
@article{Sharifzadeh2021,
author = {Sharifzadeh, Narges and Ghasemi, Ali and Tavakol Afshari, Jalil and Moharari, Fatemeh and Soltanifar, Atefeh and Talaei, Ali and Pouryousof, Hamid Reza and Nahidi, Mahsa and Fayyazi Bordbar, Mohammad Reza and Ziaee, Maliheh},
title = {Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial},
journal = {Asia-Pacific Psychiatry},
year = {2021},
volume = {13},
number = {2},
doi = {10.1111/appy.12445}
}
EUVIMED